Press Releases for DNDN

Press Releases
Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter
Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead By ImmunoCellular Therapeutics
New Cancer Immunotherapy Index Posts 23% Gains Lead By Mentor Capital, Inc. And Oncothyreon
Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
Dendreon Reports Second Quarter 2009 Financial Results
Dendreon Signs Lease for New Manufacturing Facility in Atlanta
Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
GlobalEquityReport.com Issues Market Movers Today: FEED, AIG, DNDN, BAC, GS, JPM
GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Dendreon Announces Closing of Common Stock Offering
MaybachFinancial.Com Posts Free Analyst Report on AGCO, MSFT, FEED and DNDN
Dendreon Announces Common Stock Offering
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Dendreon Reports First Quarter 2009 Financial Results
Dendreon Corp. (Nasdaq: DNDN) - Prostate Cancer Patients Benefit
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Beacon Equity Issues Trade Alerts on Market Movers: CBST, WDC, NVS, FDX, IBM, DNDN
TheFortuneFinancial.Com Initializes Free Analyst Research on VPHM, DNDN, BEAV and VRTX
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
Dendreon Reports Third Quarter 2008 Financial Results
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Dendreon Reports Second Quarter 2008 Financial Results
-Dendreon to Hold Conference Call on Tuesday, August 12, 2008 at 4:30 PM ET-
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Dendreon Announces Webcast Presentation at Needham 7th Annual Biotechnology and Medical Technology Conference
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia - May 27 2008 12:59AM
Dendreon Reports First Quarter 2008 Financial Results - Jun 1 2008 8:08PM
Aggressive Stock Alert: MIHS! April 18, 2008
Dendreon Announces Closing of Registered Direct Offering
Emerging Stock Report! April 8, 2008
BellwetherReport.com Free Analyst Review for GRMN, DNDN, KFN, and WFR
Dendreon Announces $47 Million Registered Direct Offering